Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 February 2018
|
| In: |
Journal of cancer research and clinical oncology
Year: 2018, Volume: 144, Issue: 5, Pages: 945-954 |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-018-2604-x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00432-018-2604-x
|
| Author Notes: | David M. Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia-Gutierrez, Norbert Gattermann, Philipp D. le Coutre, Bruno Martino, Susanne Saussele, Francis J. Giles, Jerald P. Radich, Giuseppe Saglio, Weiping Deng, Nancy Krunic, Véronique Bédoucha, Prashanth Gopalakrishna, Andreas Hochhaus |
| Summary: | ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis. |
|---|---|
| Item Description: | Gesehen am 29.09.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-018-2604-x |